CARDINAL HEALTH INC: Cardinal Health Announces FDA Approval of the INCRAFT® AAA Stent Graft System

Cardinal Health, Inc. issued the following announcement on Nov. 28. 

Cordis, a Cardinal Health company (NYSE: CAH), today announced that the U.S. Food and Drug Administration (FDA) has approved its INCRAFT® AAA Stent Graft System for use in complex access anatomies. The INCRAFT system is an ultra-low profile and flexible endovascular aneurysm repair (EVAR) system designed to treat infrarenal abdominal aortic aneurysms (AAA).

The INCRAFT system was given a favorable recommendation on June 12 by a Circulatory System Devices Panel of the Medical Devices Advisory Committee, following a review of clinical data from the pivotal INSPIRATION trial, a prospective, multi-center, single-arm study designed to evaluate the safety and effectiveness of the INCRAFT system in patients with AAA. The trial showed that the INCRAFT system met the primary safety and effectiveness endpoints, with a low rate of major adverse events at 30 days, high rates of successful aneurysm treatment and survival, and no aneurysm ruptures through four years of follow up.

“We welcome the recent FDA approval of the INCRAFT stent graft system which offers U.S. physicians a treatment option for patients with AAAs who otherwise might not be suitable for other EVAR devices,” said Dr. Michel Makaroun, M.D., Professor and Chair of vascular surgery at the University of Pittsburgh Medical Center, and Co-Principal Investigator of the INSPIRATION study. “While EVAR systems have advanced rapidly over the years, there still remains a need for a low-profile EVAR device that is designed to be easy to deliver in complex access anatomies while facilitating precise placement.”

“INCRAFT is an attractive new ultra-low profile EVAR option that allows for bilateral in-situ adjustment during the procedure, helping to minimize the need for additional components or extensions,” said Dr. Takao Ohki, Chairman and Professor of Surgery and Chief of Vascular Surgery at the Jikei University School of Medicine in Tokyo, Japan and Co-Principal Investigator of the INSPIRATION study.

While several EVAR devices are currently available in the U.S., treatment options are limited for many AAA patients with small femoral or iliac arteries or with heavily calcified or tortuous vessels that could lead to complications during the introduction of EVAR devices.

“We are excited to announce INCRAFT FDA approval, which will enable high-risk AAA patients in the U.S. to benefit from more than a decade of investment in R&D and clinical research,” said Patrick Holt, president of Cordis at Cardinal Health. “Cordis continues to  invest in expanding our product offering to meet our global customers’ needs, whether via innovations like our Mynx ControlTM Vascular Closure Device and our RADIAL 360 portfolio, or via strategic alliances, which brought the EluNIRTM drug-eluting coronary stent to the U.S.”  

The INCRAFT system, which received a CE (Conformité Européenne) mark in 2014, is commercially available in many global geographies, including Canada and countries in the European Union, the Middle East, South America and Asia Pacific.

Original source can be found here

Want to get notified whenever we write about Cardinal Health, Inc ?

Sign-up Next time we write about Cardinal Health, Inc, we'll email you a link to the story. You may edit your settings or unsubscribe at any time.

Organizations in this Story

Cardinal Health, Inc

More News

Metro Business Network